PEG-PLGA- hybrid nanoparticles loaded with etoricoxib – phospholipid complex for effective treatment of inflammation in rat model

Abstract

The aim of the present study was to increase the bioavailability of the etoricoxib by making PEG-PLGA-Hybrid nanoparticles using emulsion solvent evaporation method. Then the prepared nanoparticles were further characterised using TEM, particle size, PDI, zeta potential, encapsulation efficiency and drug release study. Lipid (Phospholipon 90-G) and drug thermal behaviour were studied using DSC, TGA. The results of optimised formulation of Particle size, PDI and zeta potential was found 216.6 ± 4.0 nm, 0.24 ± 0.19 and +36.3 ± 1.9 mV. Encapsulation efficiency was found in the range of 77.15% w/v to 93.88% w/v. In-vivo study shows that the optimised formulation at a particular dose decreases the swelling index and number of writhes. Stability study indicated that the nanoparticles can be stored at a temperature of 4 ± 2 °C/60 ± 5% RH in well-closed container, away from heat and damp places. The prepared formulation has significantly increased the bioavailability of etoricoxib via oral administration.

Keywords:

• Etoricoxib
• phospholipon 90-g
• PLGA (Poly{lactic co glycolic acid})
• writhing assay

Acknowledgements

Authors would like to thanks Lipoid (Germany) Lipoid GmbH for providing gift sample of polymers.

Disclosure statement

Authors declare no conflict of interest.